AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38689310
Drug: Intermittent IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent IV paracetamol
Trial: 35023349
Drug: Active low-level
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active low-level transcutaneous vagus nerve stimulation (tragus), 20 Hz, 1 mA below discomfort threshold, for 1 hour daily for 3 months.
Trial: 35023349
Drug: Sham low-level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham low-level transcutaneous vagus nerve stimulation (earlobe), 20 Hz, 1 mA below discomfort threshold, for 1 hour daily for 3 months.
Trial: 32080686
Drug: Traditional injection
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional injection (control)
Trial: 616880400
Drug: ABP-700 (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABP-700 (0.25 mg/kg and 0.35 mg/kg)
Trial: 616880400
Drug: ABP-700 (1.00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABP-700 (1.00 mg/kg)
Trial: 32356207
Drug: Daily preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily preventive zinc dispersible tablet (7 mg/d; PZ)
Trial: 32356207
Drug: Daily micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily micronutrient powder (10 mg zinc/d; MNP)
Trial: 32356207
Drug: Therapeutic zinc
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic zinc supplements for diarrhea treatment (20 mg/d for 10 days; TZ)
Trial: 32356207
Drug: Daily placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily placebo powder (Control)
Trial: 36293916
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (CC, no warm-up)
Trial: 32487035
Drug: Ipilimumab in
RxNorm normalized name: ipilimumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab in combination with nivolumab and trastuzumab
Trial: 32487035
Drug: FOLFOX in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX in combination with nivolumab and trastuzumab
Trial: 32487035
Drug: Blood-based signatures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood-based signatures (e.g. immune response or suppression of anti-HER2 resistance)
Trial: 32470434
Drug: Bortezomib–lenalidomide–dexamethasone consolidation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib–lenalidomide–dexamethasone consolidation therapy
Trial: 33593836
Drug: Anti-pseudomonal antibiotics
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-pseudomonal antibiotics
Trial: 32276603
Drug: SEIQoL-PF/G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEIQoL-PF/G
Trial: 36058429
Drug: Belimumab 10mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belimumab 10mg/kg plus standard therapy (oral glucocorticoids and either cyclophosphamide or mycophenolate mofetil)
Trial: 36058429
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus standard therapy (oral glucocorticoids and either cyclophosphamide or mycophenolate mofetil)
Trial: 34110925
Drug: Involved field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involved field radiation therapy (IFRT) in Sonic Hedgehog MB patients
Trial: 34110925
Drug: Low-dose craniospinal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose craniospinal irradiation (LDCSI) in group 4 MB patients
Trial: 32275771
Drug: Rifampicin 10
RxNorm normalized name: Rifampicine
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 10 mg/day (weak induction)
Trial: 32275771
Drug: Rifampicin 600
RxNorm normalized name: Rifampicin 600 mg powder for solution for infusion vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 600 mg/day (strong induction)
Trial: 32604939
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy sessions based on connective tissue massage
Trial: 32604939
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (ultrasound sessions without conductive gel and machine turned off)
Trial: 33558661
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly supervised impact loading and resistance exercise (ImpRes)
Trial: 34129271
Drug: Twice a
RxNorm normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice a week range of motion (ROM) exercise over a 4 weeks period
Trial: 36400737
Drug: Caring Connections
RxNorm normalized name: CONNECTING TUBE #M001229101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caring Connections (CC) intervention, a peer-based, recurrent letter writing programme designed to provide moments of positivity.
Trial: 36400737
Drug: Caring Connections
RxNorm normalized name: CONNECTING TUBE #M001229101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caring Connections (CC) intervention
Trial: 34557931
Drug: Ranger Drug‐Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranger Drug‐Coated Balloon (DCB)
Trial: 33731199
Drug: Kanglaite injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kanglaite injections (KLTi) 200 ml per day for 14 days
Trial: 33731199
Drug: First-line platinum-based
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-line platinum-based double chemotherapy regimens
Trial: 33518358
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (smoking cessation counseling and nicotine lozenges)
Trial: 34995105
Drug: Palbociclib with
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib with adjuvant endocrine therapy (ET) for 2 years
Trial: 34995105
Drug: Adjuvant endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant endocrine therapy (ET) alone
Trial: 34680134
Drug: Molecular iodine
RxNorm normalized name: molecular iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular iodine (I2) supplementation (5 mg/day)
Trial: 34680134
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with molecular iodine (Cht+I2)
Trial: 34954044
Drug: Tucatinib combination
RxNorm normalized name: tucatinib
DrugBank: Tucatinib (DB11652)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tucatinib combination (tucatinib + trastuzumab + capecitabine)
Trial: 34954044
Drug: Placebo combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combination (placebo + trastuzumab + capecitabine)
Trial: 33205906
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (methotrexate plus etanercept)
Trial: 33205906
Drug: Rescue therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue therapy (combination regimen)
Trial: 37810589
Drug: Aflibercept 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept 2.0 mg
Trial: 34550375
Drug: Low birth
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low birth weight (LBW; <2500 g)
Trial: 33884713
Drug: Extra virgin
RxNorm normalized name: Jarrow Formulas Extra Virgin Coconut Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra virgin olive oil (EVOO), 25 mL/day for 52 days
Trial: 33884713
Drug: Sunflower oil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower oil, 25 mL/day for 52 days
Trial: 34767896
Drug: PIZ >
RxNorm normalized name: Pizotifen
DrugBank: Pizotifen (DB06153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIZ > median (>14 ml)
Trial: 32057574
Drug: Standard Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Dose (SD) - 2 standard doses on weeks 0 and 4
Trial: 32057574
Drug: Double Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double Dose (DD) - 2 double-standard doses on weeks 0 and 4
Trial: 32057574
Drug: Booster Dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster Dose (BD) - 3 standard doses on weeks 0, 4, and 12
Trial: 34767030
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow aspirate concentrate (BMAC) injection
Trial: 33358336
Drug: Dexmedetomidine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.4 μg kg−1 h−1) with propofol infusion
Trial: 33358336
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline 0.9%) with propofol infusion
Trial: 32935997
Drug: Molecular-targeted treatments
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular-targeted treatments
Trial: 34689304
Drug: New galenics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New galenics nasal spray (nasic® neo)
Trial: 34689304
Drug: Comparator nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator nasal spray
Trial: 34689304
Drug: New galenics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New galenics nasal spray (nasic® neo) in subgroup with pronounced inflammation
Trial: 32907366
Drug: BMS-986141 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-986141 (400 ng/mL)
Trial: 32907366
Drug: BMS-968141 (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-968141 (combined with low-dose apixaban)
Trial: 32907366
Drug: Apixaban (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (low-dose 20 ng/mL)
Trial: 36415003
Drug: Dual task
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual task (DT) training for three weekly sessions for 8 weeks, 60 min each
Trial: 36183051
Drug: Socio-Cognitive Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Socio-Cognitive Behavioral Therapy for Suicidal Behaviors (SCBT-SB)
Trial: 33269798
Drug: Sinovac EV71
RxNorm normalized name: COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinovac EV71 vaccine (Older-S group)
Trial: 33269798
Drug: Control EV71
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control EV71 vaccine (Older-C group)
Trial: 33269798
Drug: Sinovac EV71
RxNorm normalized name: COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinovac EV71 vaccine (Younger-S group)
Trial: 32449542
Drug: Stimulation off/medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulation off/medication on condition
Trial: 33360684
Drug: Lys-FFA (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lys-FFA (500 mg EPA plus 302 mg DHA)
Trial: 33360684
Drug: EE (504
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE (504 mg EPA plus 378 mg DHA)
Trial: 33905630
Drug: OneTouch Reveal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OneTouch Reveal app (used for 12 weeks) in Subgroup C (fixed insulin dose)
Trial: 33905630
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group A, treated with continuous subcutaneous insulin infusion (CSII))
Trial: 33078435
Drug: Daily aerobic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily aerobic cycling exercise (35 min at 60% VO2max)
Trial: 32503602
Drug: BCG vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccine (0.1 ml of the licensed BCG vaccine, Danish strain 1331, SSI, Denmark, equivalent to 0.075 mg attenuated M. bovis)
Trial: 32503602
Drug: Placebo (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.1 ml 0.9% NaCl)
Trial: 35038432
Drug: Sugemalimab plus
RxNorm normalized name: Sugemalimab
DrugBank: Sugemalimab (DB16641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugemalimab plus platinum-based chemotherapy (1200 mg intravenously every 3 weeks)
Trial: 38101431
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus platinum-based chemotherapy
Trial: 35038432
Drug: Sugemalimab plus
RxNorm normalized name: Sugemalimab
DrugBank: Sugemalimab (DB16641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugemalimab plus chemotherapy
Trial: 36498288
Drug: Therapy using
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy using PNF, NDT-Bobath methods and the SPIDER system
Trial: 36498288
Drug: Therapy using
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy using PNF and NDT-Bobath methods, without the SPIDER system
Trial: 36149770
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (VITC; ∼2‐3 g)
Trial: 36149770
Drug: Oral BH4
RxNorm normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral BH4 (KUVAN, 10 mg/kg body wt)
Trial: 33517804
Drug: L-Carnitine (3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Carnitine (3000 mg daily until ovulation)
Trial: 32874108
Drug: Jump training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jump training (twice-weekly for 8 weeks)
Trial: 36263002
Drug: Remimazolam besylate
RxNorm normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam besylate (RB) combined with alfentanil (10 μg/Kg alfentanil + RB 0.2 mg/kg intravenously)
Trial: 36263002
Drug: Propofol combined
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol combined with alfentanil (10 μg/Kg alfentanil + propofol 1.5 mg/kg)
Trial: 34246485
Drug: Tegoprazan (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan (200 mg) under fasting condition
Trial: 34246485
Drug: Tegoprazan (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan (200 mg) under fed condition
Trial: 33229756
Drug: Recombinant EPO
RxNorm normalized name: EPOETIN ALFA,RECOMBINANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant EPO Beta (Recormon) administered via subcutaneous route in weekly doses of 2000 IU, 4000 IU, 6000 IU, 8000 IU, 12,000 IU, or 18,000 IU according to the severity of anemia.
Trial: 32660811
Drug: Therapeutic recommendation
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic recommendation for treatment of abnormal infant heads based on perceived deformity severity.
Trial: 35253334
Drug: Pioglitazone <15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone <15 mg/day
Trial: 35253334
Drug: Pioglitazone 15
RxNorm normalized name: pioglitazone 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 15 mg/day and 30 mg/day (pooled)
Trial: 35253334
Drug: Pioglitazone <45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone <45 mg/day
Trial: 35253334
Drug: Pioglitazone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (all doses)
Trial: 33986479
Drug: NSAID pre-operative
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NSAID pre-operative administration (Ibuprofen)
Trial: 32812384
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil group (EPA-rich fish oil: 600 mg EPA and 260 mg DHA per day for 8 weeks)
Trial: 32812384
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (matching capsules for the same duration)
Trial: 34786904
Drug: Intrauterine G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine G-CSF injections
Trial: 34786904
Drug: Intrauterine hCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine hCG injections (500 IU)
Trial: 34786904
Drug: Intrauterine saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine saline solution (placebo)
Trial: 35580701
Drug: Ketamine (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (target plasma concentration 100 ng/mL)
Trial: 33235184
Drug: Leflunomide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leflunomide (20 mg/day for 3 months)
Trial: 33235184
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of leflunomide and everolimus
Trial: 36056369
Drug: Oral diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diazepam before the operation
Trial: 36056369
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo before the operation
Trial: 32816830
Drug: Fibre-fix supplement
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibre-fix supplement added to a low FODMAP diet
Trial: 33999741
Drug: Opioid Treatment
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid Treatment Programs (OTP) in inpatient treatment
Trial: 33999741
Drug: Opioid Treatment
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid Treatment Programs (OTP)
Trial: 33710353
Drug: No skin
RxNorm normalized name: Aveeno Skin Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No skin treatment before surgery (Control)
Trial: 35460853
Drug: Type of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type of anesthesia administered
Trial: 34231532
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment for severe ROP
Trial: 34231532
Drug: Anti-VEGF treatment
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-VEGF treatment (bevacizumab) for severe ROP
Trial: 34231532
Drug: Anti-VEGF treatment
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-VEGF treatment (bevacizumab)
Trial: 32312727
Drug: Hydrosurgical debridement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrosurgical debridement ± decellularised dermal allograft, or combination with negative pressure wound therapy, as an adjunct to treatment as usual (TAU)
Trial: 32312727
Drug: One treatment
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One treatment strategy continued from phase II
Trial: 34488853
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted Cognitive Behavioural Therapy (CaCBT)
Trial: 34488853
Drug: Standard Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Cognitive Behavioural Therapy (CBT)
Trial: 32460790
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg GBS
Trial: 32460790
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg GBS
Trial: 33966113
Drug: Mesotherapy (intra‐mucosal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesotherapy (intra‐mucosal injection of ascorbic acid, 1/week for 3 weeks)
Trial: 33966113
Drug: Topical gel
RxNorm normalized name: Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel (topical ascorbic acid gel, 1/day for 3 months)
Trial: 35288066
Drug: Nivolumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (240 mg) every 2 weeks for ≤1 year
Trial: 34544599
Drug: Px563L (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Px563L (10 mcg)
Trial: 34544599
Drug: Px563L (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Px563L (50 mcg)
Trial: 34544599
Drug: Px563L (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Px563L (80 mcg)
Trial: 34544599
Drug: Px563L (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Px563L (all doses)
Trial: 35696185
Drug: Semorinemab 1500
RxNorm normalized name: Semorinemab
DrugBank: Semorinemab (DB15234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semorinemab 1500 mg
Trial: 35696185
Drug: Semorinemab 4500
RxNorm normalized name: Semorinemab
DrugBank: Semorinemab (DB15234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semorinemab 4500 mg
Trial: 35696185
Drug: Semorinemab 8100
RxNorm normalized name: Semorinemab
DrugBank: Semorinemab (DB15234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semorinemab 8100 mg
Trial: 34401684
Drug: Exteroceptive control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exteroceptive control therapy (emotional prosody identification)
Trial: 32957364
Drug: Heat-sensitive moxibustion
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-sensitive moxibustion self-administration + original antihypertensive drugs
Trial: 32957364
Drug: Original antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original antihypertensive drugs without heat-sensitive moxibustion
Trial: 35583232
Drug: High-dose clazakizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose clazakizumab (25 mg)